Motivation Behind Continuous Volunteer Participation In The Clinical Trial

Quite large numbers of clinical trials are in progress throughout the world today. Nobody can expect the progress of the clinical without volunteer participation the clinical trial. In spite of the running scarcity and public reluctant nature to participate in the clinical trial, there are number of clinical trials running with the public participation. Few factors like societal benefit are still motivating the volunteer participation in the clinical trial. 

All the participants of the clinical trial are not promised to receive the unapproved active treatment to treat their health disorder. There might be placebo as well. The placebos however escape the risk involved in the clinical trial; they do not find any progress in their health condition too. The two important motivating factors behind the volunteer participation in the clinical trial is hope of getting right cure with the advanced medication and the moral concept of benefiting the society.

The New Drug for Bowl Cancer Shows Promising Results In The Clinical Trial

Clinical trials are always on a quest to drive new medicines into the market to improve the health of the diseased. The journey of the cancer clinical trials again experienced the new results. The new drug to treat the bowel caner showed promising results in the clinical trials. Phase III results of the clinical trial demonstrated that the new drug was showing promising results in slowing down tumor growth and extended survival when compared to placebo. With the promising results shown by the drug in phase III, it was un blinded in late 2011. The independent committees of the clinical trial were offered an option to take it as it was showing a significant improvement in the survival of the patients. The drug is yet to seek the approval of FDA. Entry of the bowel cancer drug into market is gives the hope for the survival.

Clinical Trials For HIV Vaccines are On Rolls

The researcher’s effort to find the vaccine to treat the life threatening diseases HIV is waiting to open the door of final gate to enter the market. Clinical trials to test the efficiency and safety of the first HIV vaccines are under way. The HIV vaccine is formulated to target most virulent strain of the virus. It is most prevent virus in the countries like Sub Shara Africa and India, China and South America. The anti HIV shot contains trimeric HIV envelope protein (gp140) to fight against Clade C the virus responsible for causing virus in most of the patients. . The vaccine will be considered for further evaluation and testing if it found to be safe in the clinical trial. 

The vaccine is formulated to immune responsiveness following intramuscular injection. The clinical trial is on run with 36 HIV negative volunteer women aged between 18-45 years.

Delay In The Clinical Trial Publishing Affects US

Clinical trials run across the world in order to decide the efficiency and safety of the clinical trial before the drug enters into the market. Clinical trials run for a long period of time and unpublished data in the clinical trials results either in over estimation or underestimation about the efficiency of the drug that is processed in the clinical trial. The trial data published in the peer reviewed journals found to be fewer than half due to many reasons like rejection of the publications.

Clinical research discovers a medicine to treat particular diseases under uncertainty and the clinical trials confirm the efficiency of the drug. It is not that every drug that reaches the clinical trial phase is success. They may end up in failures too. If the clinical trial data is kept unpublished at the end of each and every phase, it may lead to costly mistake again. Most of the investigators depend on the peer reviewed journals for the clinical trial investigation. Lack of accessibility to the clinical trial data may evoke to investigate on the same tested formulation which leads to costly mistake again. More over this unpublished data of the clinical trials can even harm the patients in the ignorance of the risk associated with the drug.

Know Why The MPROs Are Used In The Clinical Trial

PROs patient reported outcomes refers to the questionnaires filled by the patients. The data in the PROs is collected through the self- administered questionnaire answered by the patent. The collected data becomes a PRO only when the interviewer is collecting the views of the patient, but not assess the condition of the patient based on his answers. The PRO data plays a crucial role in the clinical trial because it is collected to assess the condition of the subject by framing out the question to know about symptoms, functioning, health related quality of life and quality of life. The patient reported outcomes collected through mobile phone are called as MPRO.

The mobile patient reported outcomes give you the real time analysis with high patient compliance, real-time outcome and real-time statistics. Subjects enter the data through interactive diary programmers on a mobile phone. Once the data is downloaded into secure networks, the information is accessed by the company running the trial. The MPRO data in the clinical trial helps in reducing the timeline between the trial start and data lock.

Are Volunteers in the Clinical Trial Isolated?

The two major barriers that affect the progress of the clinical trial are recruitment and retention. It may possible for the few sponsor companies to overcome the problem of recruitment through the establishment of various advertising campaigns but, lot many fail in retaining the customer becomes the major barrier here. In most of the cases the volunteer in the clinical trial are not considered as partners, their importance in the clinical trial is treated as passive rather. 

This passiveness towards the volunteers in the clinical trial will result in the less connection between the investigator and the researcher. As there is no proper interaction established between the investigator and volunteer, he/she feels isolated in the clinical trial and the chances of leaving it are high. The solution to participant retention in the clinical trial is clear; they should be treated as active participants in the clinical trial.